Lilly COVID-19 Antibody Has Role As Stopgap When Too Late To Vaccinate

Bamlanivimab Prevented Infections In Nursing Home Residents

The company will seek emergency use authorization to prevent outbreaks in nursing homes. Regeneron is also positioning its antibody cocktail to prevent infections.

3D_Coronavirus
Eli Lilly said its antibody, bamlanivimab, is effective at preventing COVID-19 in long-term care facilities. • Source: Shutterstock

Although much attention has focused lately on vaccines to prevent SARS-CoV-2 infection, Eli Lilly and Company’s drug bamlanivimab may have a future as a way to prevent outbreaks in long-term care facilities, based on data from a Phase III study.

The Indianapolis-based drug maker said on 21 January that in the BLAZE-2 study, bamlanivimab reduced the risk of contracting COVID-19...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip